Kymera Therapeutics Prices $602 Million Public Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 hour ago0mins
- Offering Size: Kymera Therapeutics announced the pricing of 7 million shares at $86.00 each, aiming for gross proceeds of $602 million, indicating strong market confidence in its innovative drug pipeline.
- Underwriter Selection: The offering is managed by prominent financial institutions including Morgan Stanley and J.P. Morgan, which enhances investor trust in the company's future growth prospects.
- Use of Proceeds: Kymera intends to utilize the funds raised to advance its pipeline of degrader medicines targeting immunological diseases, aiming to address significant patient needs and enhance its competitive position in the market.
- Transaction Timeline: The offering is expected to close on December 11, 2025, with the potential for increased proceeds if underwriters exercise their option to purchase additional shares, reflecting optimistic market sentiment towards the company's outlook.
KYMR.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on KYMR
Wall Street analysts forecast KYMR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 73.22 USD with a low forecast of 53.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 94.300
Low
53.00
Averages
73.22
High
90.00
Current: 94.300
Low
53.00
Averages
73.22
High
90.00
Barclays
Overweight
maintain
$70 -> $119
2025-12-09
New
Reason
Barclays
Price Target
$70 -> $119
2025-12-09
New
maintain
Overweight
Reason
Barclays raised the firm's price target on Kymera Therapeutics to $119 from $70 and keeps an Overweight rating on the shares. The firm updated the company's model following the Phase 1b BroADen update. The data "significantly de-risks" KT-621's potential in T helper 2 cells driven disease, the analyst tells investors in a research note. Barclays sees share upside if KT-621 can achieve "Dupi-like sales."
Wells Fargo
Derek Archila
Overweight
maintain
$69 -> $116
2025-12-09
New
Reason
Wells Fargo
Derek Archila
Price Target
$69 -> $116
2025-12-09
New
maintain
Overweight
Reason
Wells Fargo analyst Derek Archila raised the firm's price target on Kymera Therapeutics to $116 from $69 and keeps an Overweight rating on the shares. The firm cites KT-621's positive Phase 1b results in atopic dermatitis, which also helps de-risk other indications. Wells thinks shares deserve to trade at a premium, and will also price in M&A speculation post data.
BofA
Buy
upgrade
$71 -> $112
2025-12-09
New
Reason
BofA
Price Target
$71 -> $112
2025-12-09
New
upgrade
Buy
Reason
BofA raised the firm's price target on Kymera Therapeutics to $112 from $71 and keeps a Buy rating on the shares after the company reported positive results for its Phase 1b study assessing KT-621 in moderate to severe atopic dermatitis. The firm is "encouraged" by the results, which it thinks supports KT-621 as having a clinical profile similar to dupilumab, but with a more convenient oral administration, believes the drug could expand the AD market if approved, the analyst tells investors.
Citi
Buy
upgrade
$80 -> $110
2025-12-09
New
Reason
Citi
Price Target
$80 -> $110
2025-12-09
New
upgrade
Buy
Reason
Citi raised the firm's price target on Kymera Therapeutics to $110 from $80 and keeps a Buy rating on the shares.
See All Ratings
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What were the key financial highlights from Kymera's Q3 2025 earnings call?
What is the author's perspective on Kymera's Q3 2025 performance?
How might Kymera's Q3 2025 results impact its stock performance in Q4?
What future trends could emerge for Kymera based on its Q3 2025 results?